In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amanda Micklus

Principal Analyst, Datamonitor Healthcare

Connecticut, US
Amanda has been tracking corporate strategy and business development activities in the biopharma and medtech industries for more than 10 years. She is a principal analyst with Informa’s Datamonitor Healthcare where she researches and analyzes trends in corporate strategy and dealmaking, and compiles reports for clients. Amanda also writes trends pieces for Informa’s IN VIVO and START-UP publications, and contributes to Informa’s Strategic Transactions deals database, researching and writing analyses on individual biopharma and medtech transactions. Before joining Informa, Amanda spent five years at Purdue Pharma, working as a market research analyst and information searcher. She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library & Information Science from Long Island University.
Advertisement
Set Alert for Articles By Amanda Micklus

Latest From Amanda Micklus

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical

Big Pharma Licensing Growth Slows In 2016

Big pharma licensing deal volume grew 12% between 2012 and 2016, but according to a new report from Datamonitor Healthcare there were fewer deals and dollars attributed to partnerships in 2016.

BioPharmaceutical Deals

Deals In Depth: January 2017

Servier signed a $1.7 billion immuno-oncology deal with Pieris; Johnson & Johnson paid $30 billion to acquire Actelion and its key pulmonary arterial hypertension assets. Device fundraising was significantly boosted by Verily's $800 million investment from Temasek.

Deals BioPharmaceutical

Device/Diagnostics Quarterly Deal Statistics, Q4 2016

Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.

Deals Medical Device

Biopharma Quarterly Dealmaking Statistics, Q4 2016

Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical
See All
Advertisement
UsernamePublicRestriction

Register